WHY IT MATTERS: Patients managing cancer-related appetite loss or chemotherapy-induced nerve pain may eventually have access to pharmaceutical-grade cannabinoid therapies developed specifically for those conditions rather than relying on general-use cannabis products. CLINICAL OVERVIEW: The endocannabinoid system continues to attract serious pharmaceutical investment, with companies developing targeted cannabinoid-based therapies for conditions like cancer-related anorexia and chemotherapy-induced peripheral neuropathy. These pipeline candidates represent a shift away from whole-plant preparations toward selective compounds designed to engage specific cannabinoid and related receptors with greater precision.
New Study in Pullman Shows ‘Munchies’ Might Help Those with Loss of Appetite
If you grow cannabis at home or buy from cultivators, this research on common weed killers and cancer risk highlights why clean, organic growing practices and rigorous testing matter for your safety. NBC Right Now’s local coverage of the WSU/Calgary PNAS study conducted in the Pullman community. The trial recruited 82 volunteers ages 21-62 and used a whole-plant vapor approach rather than synthetic THC to better reflect real-world use.